ReviewOncology letters2026
Subtype-specific mechanisms of lipid metabolism in gynecological malignancies and novel targeted intervention strategies (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysregulated lipid metabolism, a core metabolic hallmark of gynecological malignancies, plays a pivotal role in the initiation, progression, therapeutic resistance and prognosis of ovarian cancer, endometrial cancer and cervical cancer. Distinct pathological and molecular subtypes of ovarian, endometrial and cervical cancer exhibit highly heterogeneous and subtype-specific lipid metabolic reprogramming patterns, with core phenotypes ranging from enhanced fatty acid oxidation in high-grade serous ovarian cancer to sterol regulatory element-binding protein 1-driven lipogenesis in obesity-associated endometrial cancer and human papillomavirus-mediated cholesterol dysregulation in cervical cancer. These subtype-specific metabolic alterations drive tumor progression by mediating key malignant phenotypes, with mitochondrial lipid metabolism playing a central regulatory role in therapeutic resistance. The present review systematically summarizes the subtype-specific features of lipid metabolic dysregulation in gynecological malignancies, elaborates on the underlying molecular regulatory mechanisms, and summarizes the latest progress in lipid metabolism-targeted intervention strategies and their clinical translation. Finally, the current challenges and future directions in this field are discussed, aiming to provide new insights and theoretical support for the precision treatment of gynecological malignancies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.